Daniel Pérez Fentes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Pérez Fentes has a total of 216 co-authors. Here are the top co-authors by number of shared publications:
Miguel Blanco Parra
10 shared publicationsSerafín Novás Castro
Complejo Universitario de Santiago de Compostela
8 shared publicationsAna Puñal Pereira
7 shared publicationsM. Blanco Parra
Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela
6 shared publicationsV. Toucedo Caamaño
Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela
6 shared publicationsManuel Villar Núñez
5 shared publications
Latest Publications
- 9 November 2026
- Published by Wiley in BJU International
Sex‐related clinical characteristics and outcomes after supine PCNL and endoscopic combined intrarenal surgery: a propensity score matching analysis
Objectives: To evaluate the adjusted association between female sex and postoperative outcomes after supine percutaneous nephrolithotomy (PCNL) or endoscopic combined intrarenal surgery (ECIRS) using propensity score matching (PSM) to balance observed preoperative differences between women and men. Patients and Methods: This observational cohort study used a prospectively collected institutional database of patients undergoing supine PCNL or ECIRS between 2008 and 2025. After applying eligibility criteria, 753 patients were included. Stone‐free status was defined as complete absence of residual fragments on computed tomography performed 3 months after completion of the planned treatment episode. Safety outcomes included overall, infectious, and haemorrhagic complications, graded according to the modified Clavien–Dindo classification. A single propensity score based on pre‐specified preoperative covariates was used for one‐to‐one nearest‐neighbour matching without replacement, with a calliper of 0.2 standard deviations of the logit. Post‐matching associations were assessed using conditional logistic regression. Results: Women differed from men in baseline, stone‐related, and procedural characteristics. They were younger and had fewer cardiometabolic comorbidities, but more frequently presented positive preoperative urine cultures and greater stone complexity, as well as differences in stone composition and procedural characteristics. Before matching, female sex was associated with higher odds of infectious complications (odds ratio [OR] 2.11; P = 0.003), lower odds of haemorrhagic complications (OR 0.56; P = 0.032), and lower stone‐free rates ( P = 0.017). After PSM, 562 patients were retained. There was no statistically conclusive association between female sex and overall (OR 0.80, 95% confidence interval [CI] 0.53–1.21; P = 0.293), infectious (OR 1.16, 95% CI 0.63–2.14; P = 0.640), or haemorrhagic complications (OR 0.56, 95% CI 0.30–1.05; P = 0.068), or stone‐free status (OR 0.86, 95% CI 0.61–1.21; P = 0.381). Conclusions: Women presented a distinct preoperative profile characterised by greater infectious burden and more complex stone disease. After balancing measured preoperative characteristics, there was no statistically conclusive association between female sex and postoperative safety or stone‐free status. Sex should therefore be considered within the broader preoperative clinical context.
- 9 November 2026
- Published by Wiley in BJU International
Sex‐related clinical characteristics and outcomes after supine PCNL and endoscopic combined intrarenal surgery: a propensity score matching analysis
Objectives: To evaluate the adjusted association between female sex and postoperative outcomes after supine percutaneous nephrolithotomy (PCNL) or endoscopic combined intrarenal surgery (ECIRS) using propensity score matching (PSM) to balance observed preoperative differences between women and men. Patients and Methods: This observational cohort study used a prospectively collected institutional database of patients undergoing supine PCNL or ECIRS between 2008 and 2025. After applying eligibility criteria, 753 patients were included. Stone‐free status was defined as complete absence of residual fragments on computed tomography performed 3 months after completion of the planned treatment episode. Safety outcomes included overall, infectious, and haemorrhagic complications, graded according to the modified Clavien–Dindo classification. A single propensity score based on pre‐specified preoperative covariates was used for one‐to‐one nearest‐neighbour matching without replacement, with a calliper of 0.2 standard deviations of the logit. Post‐matching associations were assessed using conditional logistic regression. Results: Women differed from men in baseline, stone‐related, and procedural characteristics. They were younger and had fewer cardiometabolic comorbidities, but more frequently presented positive preoperative urine cultures and greater stone complexity, as well as differences in stone composition and procedural characteristics. Before matching, female sex was associated with higher odds of infectious complications (odds ratio [OR] 2.11; P = 0.003), lower odds of haemorrhagic complications (OR 0.56; P = 0.032), and lower stone‐free rates ( P = 0.017). After PSM, 562 patients were retained. There was no statistically conclusive association between female sex and overall (OR 0.80, 95% confidence interval [CI] 0.53–1.21; P = 0.293), infectious (OR 1.16, 95% CI 0.63–2.14; P = 0.640), or haemorrhagic complications (OR 0.56, 95% CI 0.30–1.05; P = 0.068), or stone‐free status (OR 0.86, 95% CI 0.61–1.21; P = 0.381). Conclusions: Women presented a distinct preoperative profile characterised by greater infectious burden and more complex stone disease. After balancing measured preoperative characteristics, there was no statistically conclusive association between female sex and postoperative safety or stone‐free status. Sex should therefore be considered within the broader preoperative clinical context.
- Open Access
- 18 July 2026
- Published by Springer Nature in Clinical and Translational Oncology
- p. 1-12
Expert consensus recommendations for the management of biochemical recurrence in prostate cancer: a Delphi study across clinical scenarios
Purpose To develop expert consensus recommendations in Spain for the management of biochemical recurrence (BCR) in prostate cancer across different clinical scenarios using a modified Delphi methodology, and to provide a multidisciplinary, evidence-based framework to inform clinical decision-making regarding definition, risk stratification, imaging, and treatment after radical prostatectomy (RP), radiotherapy (RT), and RP followed by salvage RT. Methods A multidisciplinary scientific committee formulated 51 clinical statements based on a narrative literature review and expert experience. A panel of 49 specialists, including urologists, radiation oncologists, and nuclear medicine physicians, independently rated these statements through two rounds of an online Delphi survey. Results Forty-two Spanish panelists completed both rounds. Consensus was reached for 38 of 51 statements (75%): 33 in the first round and 5 in the second. Key agreements included defining BCR after RP as a confirmed PSA rise ≥ 0.2 ng/mL; strong endorsement of next-generation imaging (NGI) for disease assessment, particularly in high-risk patients; and recommending salvage RT with or without androgen deprivation therapy (ADT) as the standard, reserving systemic therapy including androgen receptor pathway inhibitors (ARPI) for patients unsuitable for local salvage. The panel emphasized individualized ADT duration and risk-adapted imaging and treatment approaches. Additional areas of ongoing debate and future research needs were identified. Conclusions These expert-driven recommendations provide a structured clinical framework integrating current evidence and consensus guidance to optimize BCR management in prostate cancer. The findings support personalized decision-making and highlight areas requiring further prospective validation.
- 18 July 2026
- Published by Springer Nature in Clinical and Translational Oncology
- p. 1-12
Open AccessExpert consensus recommendations for the management of biochemical recurrence in prostate cancer: a Delphi study across clinical scenarios
Purpose To develop expert consensus recommendations in Spain for the management of biochemical recurrence (BCR) in prostate cancer across different clinical scenarios using a modified Delphi methodology, and to provide a multidisciplinary, evidence-based framework to inform clinical decision-making regarding definition, risk stratification, imaging, and treatment after radical prostatectomy (RP), radiotherapy (RT), and RP followed by salvage RT. Methods A multidisciplinary scientific committee formulated 51 clinical statements based on a narrative literature review and expert experience. A panel of 49 specialists, including urologists, radiation oncologists, and nuclear medicine physicians, independently rated these statements through two rounds of an online Delphi survey. Results Forty-two Spanish panelists completed both rounds. Consensus was reached for 38 of 51 statements (75%): 33 in the first round and 5 in the second. Key agreements included defining BCR after RP as a confirmed PSA rise ≥ 0.2 ng/mL; strong endorsement of next-generation imaging (NGI) for disease assessment, particularly in high-risk patients; and recommending salvage RT with or without androgen deprivation therapy (ADT) as the standard, reserving systemic therapy including androgen receptor pathway inhibitors (ARPI) for patients unsuitable for local salvage. The panel emphasized individualized ADT duration and risk-adapted imaging and treatment approaches. Additional areas of ongoing debate and future research needs were identified. Conclusions These expert-driven recommendations provide a structured clinical framework integrating current evidence and consensus guidance to optimize BCR management in prostate cancer. The findings support personalized decision-making and highlight areas requiring further prospective validation.
- 2 July 2026
- Published by Wiley in The Prostate
- Vol. 86 (13) , 1352-1366
Clinical Variable‐Based Machine Learning for Predicting Early mCRPC Using Exclusively Clinical Variables: Development and Multicenter External Validation
Background and Objective: Metastatic hormone‐sensitive prostate cancer (mHSPC) exhibits heterogeneous progression patterns, with early progression to metastatic castration‐resistant prostate cancer (mCRPC) within 12 months indicating aggressive tumor biology and poor prognosis. Current risk stratification tools (CHAARTED, LATITUDE) offer limited individualized prediction. Machine learning approaches are increasingly applied to predict prostate cancer progression, but most models show modest performance (AUC 0.68–0.72), limited external validation, or require genomic variables unavailable in routine practice. This study aimed to develop and externally validate a novel RINH algorithm for predicting early mCRPC progression (≤ 12 months) using exclusively clinical variables, positioning it as a superior alternative to conventional ML classifiers. Methods: This multicenter study enrolled 412 patients with de novo mHSPC from seven Spanish academic centers using mixed retrospective‐prospective data collection. Twenty clinical variables were recorded, including demographics, PSA, ISUP grade, metastatic localization, CHAARTED/LATITUDE classifications, and treatment modalities. Following RINH‐based outlier exclusion (55 patients), 357 patients (29 with early progression, 8.1%) were used to train six ML algorithms: RINH, Logistic Regression, Linear Discriminant, Support Vector Machine, Random Forest, and Subspace Discriminant. A two‐tiered validation strategy integrated stratified fivefold cross‐validation across all centers and formal external validation using center 1 ( n = 121, 19 events) for training and centers 2–7 ( n = 207, 10 events) for independent testing. Performance metrics included AUC, sensitivity, specificity, accuracy, and F1‐score. Key Findings and Limitations: Artificial intelligence and machine learning (ML) are transforming oncology, promising personalized risk stratification beyond traditional clinical criteria. In metastatic hormone‐sensitive prostate cancer (mHSPC), early progression to castration resistance (mCRPC) within 12 months signals aggressive biology and poor prognosis, yet current tools (CHAARTED, LATITUDE) offer limited individualized prediction. Multiple ML models have been proposed with variable success: most achieve modest performance (AUC 0.68–0.72), lack robust external validation, or rely on genomic variables inaccessible in routine practice. We propose a novel approach using the Rivality Index Neighborhood (RINH) algorithm, demonstrating superior predictive capacity in an initial multicenter validation with exclusively clinical variables. This study provides rigorous multicenter external validation, advancing toward implementable precision oncology tools. Conclusions and Clinical Implications: The RINH algorithm achieves superior predictive performance for early mCRPC progression using exclusively clinical variables, representing a significant advance toward implementable risk stratification. However, low reliability scores in external validation underscore that excellent performance metrics alone do not guarantee stability. Before clinical deployment, validation in substantially larger cohorts with higher progression events is essential. If validated, this model could enable personalized, risk‐adapted therapeutic strategies, refining patient selection for treatment intensification or de‐escalation.
- 2 July 2026
- Published by Wiley in The Prostate
- Vol. 86 (13) , 1352-1366
Clinical Variable‐Based Machine Learning for Predicting Early mCRPC Using Exclusively Clinical Variables: Development and Multicenter External Validation
Background and Objective: Metastatic hormone‐sensitive prostate cancer (mHSPC) exhibits heterogeneous progression patterns, with early progression to metastatic castration‐resistant prostate cancer (mCRPC) within 12 months indicating aggressive tumor biology and poor prognosis. Current risk stratification tools (CHAARTED, LATITUDE) offer limited individualized prediction. Machine learning approaches are increasingly applied to predict prostate cancer progression, but most models show modest performance (AUC 0.68–0.72), limited external validation, or require genomic variables unavailable in routine practice. This study aimed to develop and externally validate a novel RINH algorithm for predicting early mCRPC progression (≤ 12 months) using exclusively clinical variables, positioning it as a superior alternative to conventional ML classifiers. Methods: This multicenter study enrolled 412 patients with de novo mHSPC from seven Spanish academic centers using mixed retrospective‐prospective data collection. Twenty clinical variables were recorded, including demographics, PSA, ISUP grade, metastatic localization, CHAARTED/LATITUDE classifications, and treatment modalities. Following RINH‐based outlier exclusion (55 patients), 357 patients (29 with early progression, 8.1%) were used to train six ML algorithms: RINH, Logistic Regression, Linear Discriminant, Support Vector Machine, Random Forest, and Subspace Discriminant. A two‐tiered validation strategy integrated stratified fivefold cross‐validation across all centers and formal external validation using center 1 ( n = 121, 19 events) for training and centers 2–7 ( n = 207, 10 events) for independent testing. Performance metrics included AUC, sensitivity, specificity, accuracy, and F1‐score. Key Findings and Limitations: Artificial intelligence and machine learning (ML) are transforming oncology, promising personalized risk stratification beyond traditional clinical criteria. In metastatic hormone‐sensitive prostate cancer (mHSPC), early progression to castration resistance (mCRPC) within 12 months signals aggressive biology and poor prognosis, yet current tools (CHAARTED, LATITUDE) offer limited individualized prediction. Multiple ML models have been proposed with variable success: most achieve modest performance (AUC 0.68–0.72), lack robust external validation, or rely on genomic variables inaccessible in routine practice. We propose a novel approach using the Rivality Index Neighborhood (RINH) algorithm, demonstrating superior predictive capacity in an initial multicenter validation with exclusively clinical variables. This study provides rigorous multicenter external validation, advancing toward implementable precision oncology tools. Conclusions and Clinical Implications: The RINH algorithm achieves superior predictive performance for early mCRPC progression using exclusively clinical variables, representing a significant advance toward implementable risk stratification. However, low reliability scores in external validation underscore that excellent performance metrics alone do not guarantee stability. Before clinical deployment, validation in substantially larger cohorts with higher progression events is essential. If validated, this model could enable personalized, risk‐adapted therapeutic strategies, refining patient selection for treatment intensification or de‐escalation.
- 24 May 2026
- Published by Elsevier in Actas Urológicas Españolas (English Edition)
- Vol. 50 (7) , 501989
When evidence is not interchangeable: The limits of therapeutic equivalence in high-risk biochemical recurrence of prostate cancer
- 24 May 2026
- Published by Elsevier in Actas Urológicas Españolas (English Edition)
- Vol. 50 (7) , 501989
When evidence is not interchangeable: The limits of therapeutic equivalence in high-risk biochemical recurrence of prostate cancer
- 18 December 2025
- Published by Elsevier in Actas Urológicas Españolas
- Vol. 50 (2)
Documento de posicionamiento de la Asociación Española de Urología (AEU) y su Grupo de Urología Oncológica (GUO) sobre la prescripción de inhibidores de PARP (iPARP) en el cáncer de próstata resistente a la castración metastásico
- 18 December 2025
- Published by Elsevier in Actas Urológicas Españolas
- Vol. 50 (2)
Documento de posicionamiento de la Asociación Española de Urología (AEU) y su Grupo de Urología Oncológica (GUO) sobre la prescripción de inhibidores de PARP (iPARP) en el cáncer de próstata resistente a la castración metastásico
- Open Access
- 1 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7413
Variations in Circulating Tumor Microenvironment-Associated Proteins in Non-Muscle Invasive Bladder Cancer Induced by Mitomycin C Treatment
Mitomycin C (MMC) is a widely employed chemotherapeutic agent, particularly in non-muscle invasive bladder cancer (NMIBC), where it functions by inducing DNA cross-linking and promoting tumor cell apoptosis. However, the tumor microenvironment (TME) significantly influences the therapeutic efficacy of MMC. Among the key regulators within the TME, the complement system and the coagulation pathway play a crucial role in modulating immune responses to cancer therapies, including MMC. This article explores the interaction between platinum nanoparticles (PtNPs) with human serum (HS) of NMIBC patients (T1 and Ta subtypes) at three different points: before the chemotherapy instillation of MMC (t0) and three (t3) and six months (t6) after the treatment with MMC. This novel nanoproteomic strategy allowed the identification of a TME proteomic signature associated with the response to MMC treatment. Importantly, two proteins involved in the immune response were found to be deregulated across all patients (T1 and Ta subtypes) during MMC treatment: prothrombin (F2) downregulated and complement component C7 (C7) upregulated. By understanding how these biomarker proteins interact with MMC treatment, novel therapeutic strategies can be developed to enhance treatment outcomes and overcome resistance in NMIBC.
- 1 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7413
Open AccessVariations in Circulating Tumor Microenvironment-Associated Proteins in Non-Muscle Invasive Bladder Cancer Induced by Mitomycin C Treatment
Mitomycin C (MMC) is a widely employed chemotherapeutic agent, particularly in non-muscle invasive bladder cancer (NMIBC), where it functions by inducing DNA cross-linking and promoting tumor cell apoptosis. However, the tumor microenvironment (TME) significantly influences the therapeutic efficacy of MMC. Among the key regulators within the TME, the complement system and the coagulation pathway play a crucial role in modulating immune responses to cancer therapies, including MMC. This article explores the interaction between platinum nanoparticles (PtNPs) with human serum (HS) of NMIBC patients (T1 and Ta subtypes) at three different points: before the chemotherapy instillation of MMC (t0) and three (t3) and six months (t6) after the treatment with MMC. This novel nanoproteomic strategy allowed the identification of a TME proteomic signature associated with the response to MMC treatment. Importantly, two proteins involved in the immune response were found to be deregulated across all patients (T1 and Ta subtypes) during MMC treatment: prothrombin (F2) downregulated and complement component C7 (C7) upregulated. By understanding how these biomarker proteins interact with MMC treatment, novel therapeutic strategies can be developed to enhance treatment outcomes and overcome resistance in NMIBC.
- Open Access
- 14 November 2024
- Published by Elsevier in Asian Journal of Urology
- Vol. 12 (4) , 478-485
Percutaneous nephrolithotomy in pregnancy: A comprehensive review and technical insights
- 14 November 2024
- Published by Elsevier in Asian Journal of Urology
- Vol. 12 (4) , 478-485
Open AccessPercutaneous nephrolithotomy in pregnancy: A comprehensive review and technical insights
- Open Access
- 10 September 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (9) , 962
Predicting and Avoiding Complications in Percutaneous Nephrolithotomy in the Era of Personalized Medicine: A Scoping Review
Background: Percutaneous nephrolithotomy (PCNL) is associated with a wide range of complications. This review aims to explore how recent technological advancements and personalized medicine can help prevent or predict these complications. Methods: A scoping review was conducted according to the PRISMA-SCR guidelines and registered on the Open Science Framework in April 2024. A literature search was performed on PUBMED, Web of Science, and Scopus databases. This review focused on predictive AI models, 3D surgical models, intrasurgical image guidance, and biomarkers. Articles meeting the following criteria were included: publication between 2019 and 2024, written in English, involving human participants, and discussing technological advancements or personalized medicine in the context of complications in PCNL. Results: Of the 11,098 articles searched, 35 new studies were included. We identified a few articles on predictive AI models. Several studies demonstrated that 3D presurgical models and virtual models could enhance surgical planning and reduce complications. New intrasurgical image and guidance systems showed the potential in reducing bleeding and radiation exposure. Finally, several biomarkers were identified as predictors of sepsis and other complications. Conclusion: This scoping review highlights the potential of emerging technologies in reducing and predicting PCNL complications. However, larger prospective studies are required for validation.
- 10 September 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (9) , 962
Open AccessPredicting and Avoiding Complications in Percutaneous Nephrolithotomy in the Era of Personalized Medicine: A Scoping Review
Background: Percutaneous nephrolithotomy (PCNL) is associated with a wide range of complications. This review aims to explore how recent technological advancements and personalized medicine can help prevent or predict these complications. Methods: A scoping review was conducted according to the PRISMA-SCR guidelines and registered on the Open Science Framework in April 2024. A literature search was performed on PUBMED, Web of Science, and Scopus databases. This review focused on predictive AI models, 3D surgical models, intrasurgical image guidance, and biomarkers. Articles meeting the following criteria were included: publication between 2019 and 2024, written in English, involving human participants, and discussing technological advancements or personalized medicine in the context of complications in PCNL. Results: Of the 11,098 articles searched, 35 new studies were included. We identified a few articles on predictive AI models. Several studies demonstrated that 3D presurgical models and virtual models could enhance surgical planning and reduce complications. New intrasurgical image and guidance systems showed the potential in reducing bleeding and radiation exposure. Finally, several biomarkers were identified as predictors of sepsis and other complications. Conclusion: This scoping review highlights the potential of emerging technologies in reducing and predicting PCNL complications. However, larger prospective studies are required for validation.